Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

iBio (IBIO) EBITDA Margin (2016 - 2025)

iBio (IBIO) has disclosed EBITDA Margin for 16 consecutive years, with 5735.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 5735.0% in Q3 2025 year-over-year; TTM through Dec 2025 was 8260.0%, a 415653.0% decrease, with the full-year FY2025 number at 4650.5%, up 274239.0% from a year prior.
  • EBITDA Margin was 5735.0% for Q3 2025 at iBio, down from 2599.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 377.11% in Q1 2022 to a low of 10206.0% in Q3 2023.
  • A 5-year average of 3576.89% and a median of 2182.0% in 2024 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 323111bps in 2021; the steepest drop was -453146bps in 2021.
  • iBio's EBITDA Margin stood at 6220.24% in 2021, then surged by 94bps to 377.11% in 2022, then crashed by -2606bps to 10206.0% in 2023, then surged by 79bps to 2182.0% in 2024, then plummeted by -163bps to 5735.0% in 2025.
  • Per Business Quant, the three most recent readings for IBIO's EBITDA Margin are 5735.0% (Q3 2025), 2599.0% (Q2 2025), and 2182.0% (Q4 2024).